Literature DB >> 8690044

Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.

M Torcia1, M Lucibello, E Vannier, S Fabiani, A Miliani, G Guidi, O Spada, S K Dower, J E Sims, A R Shaw, C A Dinarello, E Garaci, F Cozzolino.   

Abstract

We have studied the effects of several interleukin-1 (IL-1) inhibitors--IL-1 receptor antagonist (IL-1ra), soluble IL-1 receptor (sIL-1R) types I and II, and neutralizing monoclonal antibody (mAb) specific for IL-1 receptor type I--on the osteoclast-activating factor (OAF) activity of recombinant IL-1beta and of culture supernatants of unfractionated bone marrow mononuclear cells from multiple myeloma (MM) patients. The latter activity sharply correlated with the IL-1 content of culture supernatants (r = 0.949; p < 0.001). IL-1ra and sIL-1R types I and II had a clear-cut modulating effect on the OAF activity of IL-1beta at saturating doses (2-10 ng/mL); their effect was evident at 2 ng/mL and was dose-dependent over a large range of concentrations. Similarly, the three reagents neutralized the OAF activities of all MM cell supernatants in a dose-dependent fashion and completely abolished them when tested at the fixed concentration of 5 nM. The bone-resorbing activity of tumor necrosis factor-alpha (TNF-alpha) or lymphotoxin (LT), tested alone or added to MM cell supernatants, was affected not at all by IL-1ra and only minimally by sIL-1R types I and II, suggesting that little or no endogenous IL-1 was produced by the rat cells in the assay under TNF-alpha or LT stimulation. Consistent with these findings, PGE2 production elicited by IL-1beta or IL-1-rich supernatants in the rat long-bone assay was abolished by each reagent. Also, mAbs to the IL-1R p80 (type I) chains could modulate the effects of IL-1--recombinant or plasma cell-derived--in the OAF assay, but their activity was markedly less pronounced when compared with the IL-1 inhibitors, since they could never completely abolish bone resorption. Taken together, these findings demonstrate that inhibition of IL-1 interaction with cognate surface receptors on bone cells effectively counteracts its biologic activity. The findings also strongly indicate that OAF activity in conditioned medium of unfractionated myeloma bone marrow cells is predominantly, if not solely, related to IL-1beta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690044

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  Blocking interleukin-1β in acute and chronic autoinflammatory diseases.

Authors:  C A Dinarello
Journal:  J Intern Med       Date:  2011-01       Impact factor: 8.989

2.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

3.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 4.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

5.  Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption.

Authors:  R J van't Hof; K J Armour; L M Smith; K E Armour; X Q Wei; F Y Liew; S H Ralston
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

6.  Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.

Authors:  Paweł Robak; Edyta Węgłowska; Izabela Dróżdż; Damian Mikulski; Dariusz Jarych; Magdalena Ferlińska; Ewa Wawrzyniak; Małgorzata Misiewicz; Piotr Smolewski; Wojciech Fendler; Janusz Szemraj; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2020-06-06       Impact factor: 4.711

7.  Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a multicenter randomized double-blind placebo-controlled trial.

Authors:  Charlotte E M de Mooij; Lenneke F J van Groningen; Anton F J de Haan; Bart J Biemond; Martijn Bakker; Walter J F M van der Velden; Nicole M A Blijlevens
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.